{"id":530328,"date":"2021-08-23T07:33:46","date_gmt":"2021-08-23T11:33:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/"},"modified":"2021-08-23T07:33:46","modified_gmt":"2021-08-23T11:33:46","slug":"athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/","title":{"rendered":"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOTHELL, Wash., Aug.  23, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l6NpbsRv2DaHx1ch2Tn3BzLOEtW11SqD-kH-v-o-6qeIWJe7pojFLUunK1sd9quB3kJW6I95i7a94A3nuHJJdg==\" rel=\"nofollow noopener\" target=\"_blank\">Athira Pharma, Inc.<\/a> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer\u2019s drug development, and the utility of ERP P300 in Athira\u2019s Phase 1 clinical trials, at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wQSRUqHrAvs7lHLmMjrCgkz2KrRe-w0vrAxncesCdXtttk9l4f_zrc0Gl4msVvraXrL48hbIm8D0sKz_YNomULJ4VDcdv4QOc2vvgFr73NT7tCiSsIsiIFsfO4VCnz1h1nLlm5h-9609U2i7OAsWPUXvgaIRQ0kQ-TkvDvObe_U=\" rel=\"nofollow noopener\" target=\"_blank\">Annual Biomarkers for Alzheimer\u2019s Disease Summit<\/a> taking place virtually August 24-26, 2021.<\/p>\n<p>\n        <strong>Presentation Details<\/strong>:<\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0Advances in Direct, Functional, Non-Invasive Biomarkers; Athira\u2019s Utilization of ERP P300<br \/><strong>Presenter: <\/strong>Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma, Inc.<br \/><strong>Date: <\/strong>Wednesday, August 25, 2021<br \/><strong>Time: <\/strong>12:10 p.m. PT \/ 3:10 p.m. ET<\/p>\n<p>\n        <strong>About Athira Pharma, Inc.<\/strong><br \/>\n        <br \/>Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer\u2019s and Parkinson\u2019s dementia. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_a8whyuMcsalzJPAvAlKWeC2kzf4Y21XBx72jXzMaPftwQJDLKwLCH_LiQVQb6ql7hL9edMGDXWDPU7xZWEEVw==\" rel=\"nofollow noopener\" target=\"_blank\">www.athira.com<\/a>. You can also follow Athira on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aictDCJ5Fxx69o_bo20fp8jcZO43ke-PaCeKcTD0Y0IuDcEf5MuMoQDOHN0PObf5DkMcALyF81kKZ4wbB1u37wWWOFjtggAP-M3C12aChxw=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7v8I9kR0Ikd_SwtftxDNQmqR2uYvRgaS3FgIlf6sHsV0HfVhAa6LHacKlWT0PPDwyeojOpufsbDQziOtUljXjnLo0IFtenkNPzF9lZaNcXg=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0@athirapharma on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AM20azP2DxrN9gwWq9sNua2WtGc2u0fPGjgUhBpjfTFgifkAPFqucxbGBcCtCijqrBOCiyJwRY4TD78_L3Dr9LUVQeMXvyjMVaamIeotoS0=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qmHz60-c2ofU3tjDoC5h9lEuYh_XuL0Gd9LF1N8eYSxI2Ld0CvKP0o0tLWYEp-zfOR8mRr457kPFKDQ-NgN0THrvTWsMVwdbyBtpMoe38dY=\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact:<\/strong><br \/>\n        <br \/>Julie Rathbun<br \/>Athira Pharma, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ifgCsyQ-JzoZxgnEZaBMrQ5YSnaaKycEeJTFw90DZUGlEjVfch44zS8OAWwC0gVKPlrSiFYqIwxICvScT4J4Wwxnk76l-6_5ds0OWPFzXtE=\" rel=\"nofollow noopener\" target=\"_blank\">Julie.rathbun@athira.com<\/a>\u00a0<br \/>206-769-9219<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTZmNjYzODEtM2Y4NC00MzMyLTg2MTItNjEyYzg1NWJlNjg4LTEyMTM0NDQ=\/tiny\/Athira-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer\u2019s drug development, and the utility of ERP P300 in Athira\u2019s Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer\u2019s Disease Summit taking place virtually August 24-26, 2021. Presentation Details: Title:\u00a0Advances in Direct, Functional, Non-Invasive Biomarkers; Athira\u2019s Utilization of ERP P300Presenter: Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma, Inc.Date: Wednesday, August 25, 2021Time: 12:10 p.m. PT \/ 3:10 p.m. ET About Athira &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-530328","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer\u2019s drug development, and the utility of ERP P300 in Athira\u2019s Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer\u2019s Disease Summit taking place virtually August 24-26, 2021. Presentation Details: Title:\u00a0Advances in Direct, Functional, Non-Invasive Biomarkers; Athira\u2019s Utilization of ERP P300Presenter: Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma, Inc.Date: Wednesday, August 25, 2021Time: 12:10 p.m. PT \/ 3:10 p.m. ET About Athira &hellip; Continue reading &quot;Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-23T11:33:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit\",\"datePublished\":\"2021-08-23T11:33:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/\"},\"wordCount\":244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/\",\"name\":\"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=\",\"datePublished\":\"2021-08-23T11:33:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/","og_locale":"en_US","og_type":"article","og_title":"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit - Market Newsdesk","og_description":"BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer\u2019s drug development, and the utility of ERP P300 in Athira\u2019s Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer\u2019s Disease Summit taking place virtually August 24-26, 2021. Presentation Details: Title:\u00a0Advances in Direct, Functional, Non-Invasive Biomarkers; Athira\u2019s Utilization of ERP P300Presenter: Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma, Inc.Date: Wednesday, August 25, 2021Time: 12:10 p.m. PT \/ 3:10 p.m. ET About Athira &hellip; Continue reading \"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-23T11:33:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit","datePublished":"2021-08-23T11:33:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/"},"wordCount":244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/","name":"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=","datePublished":"2021-08-23T11:33:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMzQ0MCM0MzcwNDI3IzIyMDE4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the-annual-biomarkers-for-alzheimers-disease-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer\u2019s Disease Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/530328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=530328"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/530328\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=530328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=530328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=530328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}